Table 2 Demographic and clinical characteristics of the sample (N = 498)
Country, n (%) | |
 Austria (Innsbruck & Graz) | 61 (12.2%) |
 Croatia (Rijeka) | 33 (6.6%) |
 France (Paris) | 52 (10.4%) |
 Germany (Regensburg) | 53 (10.6%) |
 Greece (Athens) | 15 (3.0%) |
 India (Silchar) | 52 (10.4%) |
 Italy (Rome) | 33 (6.6%) |
 Japan (Kobe & Tokyo) | 31 (6.2%) |
 Jordan (Amman) | 55 (11.0%) |
 Poland (Rzeszów) | 13 (2.6%) |
 Portugal (Ponta Delgada) | 30 (6.0%) |
 Spain (Pamplona) | 52 (10.4%) |
 United Kingdom (Poole) | 18 (3.6%) |
Cultural area, n (%) | |
 Non-European country | 138 (27.7%) |
 Northern Europe | 114 (22.9%) |
 Southern Europe | 215 (43.2%) |
 Eastern Europe | 13 (2.6%) |
 English-speaking (UK) | 18 (3.6%) |
Sociodemographic | |
 Age, mean (SD) | 62.1 (13.5) |
Age groups, n (%) | |
  ≤ 50 years | 102 (20.5%) |
 50 – 70 years | 242 (48.7%) |
  > 70 years | 153 (30.8%) |
 Missing | 1 |
Sex, n (%) | |
 Male | 220 (45.1%) |
 Female | 268 (54.9%) |
 Missing | 10 |
Highest level of education, n (%) | |
 Less than compulsory school education | 59 (12.1%) |
 Compulsory school education | 172 (35.3%) |
 Post-compulsory education below university level | 135 (27.7%) |
 University level | 121 (24.8%) |
 Missing | 11 |
Clinical information at study entry | |
 Anatomical location of the primary tumour, n (%) | |
  Lung | 86 (17.4%) |
  Colorectal | 36 (7.3%) |
  Breast | 147 (29.8%) |
  Gynaecologic system (ovarian. endometrium. cervix) | 35 (7.1%) |
  Head and neck | 42 (8.5%) |
  Prostate | 27 (5.5%) |
  Other genito-urinary (kidney, ureter, bladder, testis) | 12 (2.4%) |
  Oesophageal, stomach | 27 (5.5%) |
  Brain | 13 (2.6%) |
  Haematological | 10 (2.0%) |
  Other | 59 (11.9%) |
  Missing | 4 |
Known current disease stage, n (%) | |
 Initial | 254 (51.7%) |
 Advanced | 237 (48.3%) |
 Missing | 7 |
Co-morbidity (other serious medical conditions), n (%) | |
 Yes | 98 (20.0%) |
 No | 391 (80.0%) |
 Missing | 9 |
Treatment site, n (%) | |
 Outpatient | 347 (70.0%) |
 Inpatient | 149 (30.0%) |
 Missing | 2 |
Treatment intention | |
 Radical/curative | 283 (57.4) |
 Palliative/symptom relief | 215 (42.6 |
Previous treatment | |
 Surgery, n (%) | |
  Yes | 251 (56.2%) |
  No | 196 (43.8%) |
  Missing | 51 |
Chemotherapy, n (%) | |
 Yes | 207 (45.3%) |
 No | 250 (54.7%) |
 Missing | 41 |
Radiotherapy, n (%) | |
 Yes | 135 (29.8%) |
 No | 318 (70.2%) |
 Missing | 45 |
Hormonotherapy, n (%) | |
 Yes | 61 (14.0%) |
 No | 376 (86.0%) |
 Missing | 61 |
Targeted therapy, n (%) | |
 Yes | 42 (9.6%) |
 No | 394 (90.4%) |
 Missing | 62 |
In relation to the visits at the second assessment | |
 Did you have a companion with you at the visits with the professional assessed (a relative or other person), n (%) | |
  No companion | 72 (24.9%) |
  Sometimes | 74 (25.6%) |
  Always | 143 (49.5%) |
  Missing | 209 |
Current treatment at the second assessment | |
 Surgery, n (%) | |
  Yes | 16 (5.8%) |
  No | 260 (94.2%) |
  Missing | 222 |
Chemotherapy, n (%) | |
 Yes | 142 (49.7%) |
 No | 144 (50.3%) |
 Missing | 212 |
Radiotherapy, n (%) | |
 Yes | 49 (17.7%) |
 No | 228 (82.3%) |
 Missing | 221 |
Hormonotherapy, n (%) | |
 Yes | 30 (10.9%) |
 No | 245 (89.1%) |
 Missing | 223 |
Targeted therapy, n (%) | |
 Yes | 22 (8.0%) |
 No | 254 (92.0%) |
 Missing | 222 |